Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jan;38(1):159–160. doi: 10.1128/aac.38.1.159

Retain intermittent dosing of carbapenems.

H Hanberger, L E Nilsson
PMCID: PMC284416  PMID: 8141574

Full text

PDF
159

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Craig W. A., Ebert S. C. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother. 1992 Dec;36(12):2577–2583. doi: 10.1128/aac.36.12.2577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Craig W. A. Outpatient parenteral antibiotic therapy. Management of serious infections. Part I: Medical, socioeconomic, and legal issues. Selecting the antibiotic. Hosp Pract (Off Ed) 1993 Jun;28 (Suppl 1):16–20. doi: 10.1080/21548331.1993.11442930. [DOI] [PubMed] [Google Scholar]
  3. Drusano G. L., Plaisance K. I., Forrest A., Bustamante C., Devlin A., Standiford H. C., Wade J. C. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother. 1987 Sep;31(9):1420–1422. doi: 10.1128/aac.31.9.1420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Drusano G. L. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother. 1988 Mar;32(3):289–297. doi: 10.1128/aac.32.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Flückiger U., Segessenmann C., Gerber A. U. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model. Antimicrob Agents Chemother. 1991 Sep;35(9):1905–1910. doi: 10.1128/aac.35.9.1905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Flückiger U., Segessenmann C., Gerber A. U. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model. Antimicrob Agents Chemother. 1991 Sep;35(9):1905–1910. doi: 10.1128/aac.35.9.1905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hanberger H., Nilsson L. E., Nilsson M., Maller R. Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC. Eur J Clin Microbiol Infect Dis. 1991 Nov;10(11):927–934. doi: 10.1007/BF02005446. [DOI] [PubMed] [Google Scholar]
  8. Liang R., Yung R., Chiu E., Chau P. Y., Chan T. K., Lam W. K., Todd D. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother. 1990 Jul;34(7):1336–1341. doi: 10.1128/aac.34.7.1336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Nilsson L., Nilsson M., Jendle J. Subpopulations of variants resistant to imipenem in Pseudomonas aeruginosa. J Antimicrob Chemother. 1988 Nov;22(5):643–649. doi: 10.1093/jac/22.5.643. [DOI] [PubMed] [Google Scholar]
  10. Quinn J. P., Studemeister A. E., DiVincenzo C. A., Lerner S. A. Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms. Rev Infect Dis. 1988 Jul-Aug;10(4):892–898. doi: 10.1093/clinids/10.4.892. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES